Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Interim results from Seattle Genetics’ ASG-5ME phase I trial on metastatic PDA

Interim results from Seattle Genetics’ ASG-5ME phase I trial on metastatic PDA

New model of tau pathology spread

New model of tau pathology spread

FDA approves Santarus’ UCERIS for induction of remission in patients with ulcerative colitis

FDA approves Santarus’ UCERIS for induction of remission in patients with ulcerative colitis

Results from Morphotek’s farletuzumab Phase III combination study on ovarian cancer

Results from Morphotek’s farletuzumab Phase III combination study on ovarian cancer

arGEN-X commences ARGX-110 Phase Ib trial to treat cancer

arGEN-X commences ARGX-110 Phase Ib trial to treat cancer

Adrenomed creates Adrecizumab to decrease death rates from sepsis

Adrenomed creates Adrecizumab to decrease death rates from sepsis

EPIRUS’ BOW-015 achieves bioequivalence to Remicade in a single dose comparator trial

EPIRUS’ BOW-015 achieves bioequivalence to Remicade in a single dose comparator trial

OncoMed commences dosing in OMP-52M51 Phase 1 clinical trial for hematologic cancers

OncoMed commences dosing in OMP-52M51 Phase 1 clinical trial for hematologic cancers

Acorda Therapeutics acquires Neuronex

Acorda Therapeutics acquires Neuronex

US FDA approves raxibacumab for treating inhalational anthrax

US FDA approves raxibacumab for treating inhalational anthrax

GSK receives FDA approval for raxibacumab to treat inhalational anthrax

GSK receives FDA approval for raxibacumab to treat inhalational anthrax

Eli Lilly provides update on solanezumab Phase 3 clinical study for mild Alzheimer's

Eli Lilly provides update on solanezumab Phase 3 clinical study for mild Alzheimer's

Inotuzumab ozogamicin selectively destroys malignant cells responsible for ALL in weekly dosing

Inotuzumab ozogamicin selectively destroys malignant cells responsible for ALL in weekly dosing

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

Celldex announces final results from CDX-011 Phase 2b study on GPNMB-expressing breast cancer

Celldex announces final results from CDX-011 Phase 2b study on GPNMB-expressing breast cancer

Targeted therapy as common as chemotherapy at end of life

Targeted therapy as common as chemotherapy at end of life

14 new human monoclonal antibodies introduced by Beckman Coulter Life Sciences

14 new human monoclonal antibodies introduced by Beckman Coulter Life Sciences

ArmaGen closes $17M Series A financing

ArmaGen closes $17M Series A financing

NovImmune commences NI-0101 Phase I clinical trial in arthritis

NovImmune commences NI-0101 Phase I clinical trial in arthritis

Renowned biotech researcher to receive TJU's Lennox K. Black International Prize

Renowned biotech researcher to receive TJU's Lennox K. Black International Prize

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.